Biased Ligands. Better Drugs.

Trevena to Present at Investor Conferences in June
6/2/17

Trevena, Inc. (NASDAQ:TRVN) today announced that it will be attending the following investor conferences in June:

  • Jefferies 2017 Global Healthcare Conference on Thursday, June 8, 2017, at 3:00 p.m. EDT in New York;
  • 2017 Marcum Microcap Conference on Thursday, June 15, 2017, at 10:00 a.m. EDT in New York;
  • JMP Securities Life Sciences Conference on Wednesday, June 21, 2017, at 8:30 a.m. EDT in New York.

The Jefferies and Marcum presentations will be webcast live. To join, please visit the Investor section of the Company’s website. Following the conclusion of each presentation, the webcast will be available for replay for 30 days.

About Trevena

Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection), currently in Phase 3 development for the management of moderate-to-severe acute pain. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.

Contacts

Trevena, Inc.

Investors:
Jonathan Violin, Ph.D.
Vice President, Corporate Strategy & Investor Relations
610-354-8840 x231
jviolin@trevena.com

or

Media:
Public Relations
PR@trevena.com

Copyright © Trevena, Inc.